Critical Analysis: Ikena Oncology (NASDAQ:IKNA) versus Fresh Tracks Therapeutics (NASDAQ:FRTX)

Ikena Oncology (NASDAQ:IKNA) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Profitability

This table compares Ikena Oncology and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ikena Oncology	N/A	-36.88%	-33.08%
Fresh Tracks Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and target prices for Ikena Oncology and Fresh Tracks Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ikena Oncology	0	1	1	0	2.50
Fresh Tracks Therapeutics	0	0	0	0	0.00

Ikena Oncology currently has a consensus price target of $3.00, indicating a potential upside of 78.57%. Given Ikena Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Ikena Oncology is more favorable than Fresh Tracks Therapeutics.

Insider & Institutional Ownership

75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Ikena Oncology and Fresh Tracks Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ikena Oncology	$659,000.00	123.02	-$68.17 million	($1.23)	-1.37
Fresh Tracks Therapeutics	$8.01 million	0.53	-$5.69 million	($1.41)	-0.51

Fresh Tracks Therapeutics has higher revenue and earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ikena Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Summary

Ikena Oncology beats Fresh Tracks Therapeutics on 7 of the 12 factors compared between the two stocks.

About Ikena Oncology

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.